Julie Guillermet-Guibert

Title: Innovations by Julie Guillermet-Guibert

Introduction

Julie Guillermet-Guibert is a prominent inventor based in Toulouse, France. She has made significant contributions to the field of cancer research, particularly in understanding the PI3K signaling pathway. With a total of 2 patents, her work focuses on developing innovative strategies for predicting sensitivity to cancer treatments.

Latest Patents

One of her latest patents is a marker for predicting sensitivity to PI3K inhibitors. This invention addresses the challenge of heterogeneity in PI3K expression patterns in tumoral samples. By identifying a specific phosphopeptide, characterized by the amino acid sequence PGPSDHQSQEASQFER, the invention provides insights into selecting appropriate PI3K-targeting drugs. Another notable patent involves combination treatment for pancreatic cancer. This research challenges existing concepts by mapping differential isoform-specific downstream signaling in response to selective inhibition. The findings suggest that combined inhibition of p110α and p110γ is the most effective strategy for treating pancreatic cancer patients.

Career Highlights

Julie has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université Paul Sabatier (Toulouse III). Her research has significantly advanced the understanding of cancer treatment options.

Collaborations

Some of her notable coworkers include Célia Cintas and Thibaut Douche. Their collaborative efforts have contributed to the success of her innovative projects.

Conclusion

Julie Guillermet-Guibert's work exemplifies the impact of innovation in cancer research. Her patents and collaborations highlight her commitment to improving treatment strategies for patients.